Cassava Sciences Stock (NASDAQ:SAVA)

Forecast Ownership Financials Chart

Previous Close

$1.29

52W Range

$1.15 - $4.98

50D Avg

$2.12

200D Avg

$2.51

Market Cap

$63.77M

Avg Vol (3M)

$857.77K

Beta

-0.84

Div Yield

SAVA Company Profile

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 14, 2000

Website

SAVA Performance

SAVA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-141.45M	$-105.96M
Net Income	$-90.97M	$-24.34M	$-97.22M
EBITDA	-	$-141.15M	$-104.43M
Basic EPS	$-1.88	$-0.53	$-2.32
Diluted EPS	$-1.88	$-0.52	$-2.32

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 07, 24 | 8:30 AM

Q2 24Aug 08, 24 | 8:30 AM

Q3 18Oct 29, 18 | 4:30 AM

Peer Comparison

Ticker	Company
MIST	Milestone Pharmaceuticals Inc.
MOLN	Molecular Partners AG
ALEC	Alector, Inc.
CRDF	Cardiff Oncology, Inc.
NKTX	Nkarta, Inc.
FATE	Fate Therapeutics, Inc.
RANI	Rani Therapeutics Holdings, Inc.
ELTX	Elicio Therapeutics, Inc.
PEPG	PepGen Inc.